Clinical Trial Update: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and efficacy of Intracystic TARA-002 for treating lymphatic malformations in children aged 6 months to under 18; recruitment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphatic Malformation

Drugs mentioned

• TARA-002

Snippet

Sponsor: Protara Therapeutics | Conditions: Lymphatic Malformation | Phase 2 | Status: RECRUITING